Therapeutic role of probiotics in motor and non-motor symptoms of Parkinson’s disease

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms, in which gut microbiota alterations have emerged as a potential pathogenic factor, causing disruption of the brain-gut-microbiota (BGM) axis. Recent evidence supports the role of BGM axis disruption in enhancing neuroinflammation, alpha-synuclein (α-syn) aggregation, and dopaminergic neurodegeneration. Emerging therapeutic strategies targeting dysbiosis, such as probiotics and fecal microbiota transplantation (FMT), have become a new focus of investigation for PD treatment. Proposed mechanisms include modulation of immune responses, enhancement of intestinal barrier integrity, production of neuroactive metabolites such as short-chain fatty acids, and reduction of oxidative stress. This narrative review summarizes current evidence on probiotics as a therapeutic strategy in PD. By analyzing data from randomized controlled trials and preclinical studies, we highlight the beneficial effects of probiotics in improving motor and non-motor symptoms of PD, including constipation, depression, and anxiety. Strains such as Lactobacillus plantarum PS128 and Bifidobacterium animalis Probio-M8 show particular promise. Although probiotics have demonstrated a favorable safety profile and potential as an adjunctive therapy for PD, future research should focus on standardized protocols, biomarker identification, and exploration of combined microbiota-targeted strategies.

Keywords

Parkinson’s disease / gut-brain axis / microbiota / probiotics / neuroinflammation / non-motor symptoms / motor symptoms

References

[1] Zhu J, Cui Y, Zhang J, Yan R, Su D, Zhao D, et al. Temporal trends in the prevalence of Parkinson’s disease from 1980 to 2023: a systematic review and meta-analysis. Lancet Healthy Longev. 2024; 5: e464-79.

[2] Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021; 20: 385-97.

[3] Gikoska M, Gilbert T, Wierzbicki LA, Thompson AR. Dysbiosis of the Gut Microbiota Being a Contributing Factor to Parkinson’s Disease: A Literature Review. Preprints 202410.0016.v1 [Preprint]. 2024 [cited 2025 Jul 27]. Available from: https://www.preprints.org/manuscript/202410.0016

[4] Kouli A, Torsney KM, Kuan W. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon; 2018. pp. 3-26.

[5] Feng M, Zou Z, Shou P, Peng W, Liu M, Li X. Gut microbiota and Parkinson’s disease: potential links and the role of fecal microbiota transplantation. Front Aging Neurosci. 2024; 16: 1479343.

[6] Yemula N, Dietrich C, Dostal V, Hornberger M. Parkinson’s Disease and the Gut: Symptoms, Nutrition, and Microbiota. J Parkinsons Dis. 2021; 11: 1491-505.

[7] Nabil Y, Helal MM, Qutob IA, Dawoud AIA, Allam S, Haddad R, et al. Efficacy and safety of fecal microbiota transplantation in the management of parkinson’s disease: a systematic review. BMC Neurol. 2025; 25: 291.

[8] Kim S, Kwon S, Kam T, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease. Neuron. 2019; 103: 627-41.e7.

[9] Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014; 128: 805-20.

[10] Caradonna E, Nemni R, Bifone A, Gandolfo P, Costantino L, Giordano L, et al. The Brain-Gut Axis, an Important Player in Alzheimer and Parkinson Disease: A Narrative Review. J Clin Med. 2024; 13: 4130.

[11] Yadav S, Raj RG. Parkinson’s disease and the gut microbiota connection: unveiling dysbiosis and exploring therapeutic horizons. Neuroscience. 2025; 581: 1-15.

[12] Benvenuti L, Salvo CD, Bellini G, Seguella L, Rettura F, Esposito G, et al. Gut-directed therapy in Parkinson’s disease. Front Pharmacol. 2024; 15: 1407925.

[13] Chu C, Yu L, Li Y, Guo H, Zhai Q, Chen W, et al. Meta-analysis of randomized controlled trials of the effects of probiotics in Parkinson’s disease. Food Funct. 2023; 14: 3406-22.

[14] Xie L, Chen D, Zhu X, Cheng C. Efficacy and safety of probiotics in Parkinson’s constipation: A systematic review and meta-analysis. Front Pharmacol. 2023; 13: 1007654.

[15] Jin X, Dong W, Chang K, Yan Y, Liu X. Efficacy of probiotic supplements on Parkinson’s disease: A systematic review and meta-analysis. Complement Ther Med. 2024; 82: 103045.

[16] Leta V, Chaudhuri KR, Milner O, Chung-Faye G, Metta V, Pariante CM, et al. Neurogenic and anti-inflammatory effects of probiotics in Parkinson’s disease: A systematic review of preclinical and clinical evidence. Brain Behav Immun. 2021; 98: 59-73.

[17] Tsao S, Nurrahma BA, Kumar R, Wu C, Yeh T, Chiu C, et al. Probiotic Enhancement of Antioxidant Capacity and Alterations of Gut Microbiota Composition in 6-Hydroxydopamin-Induced Parkinson’s Disease Rats. Antioxidants (Basel). 2021; 10: 1823.

[18] Castelli V, d’Angelo M, Lombardi F, Alfonsetti M, Antonosante A, Catanesi M, et al. Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models. Aging (Albany NY). 2020; 12: 4641-59.

[19] Magistrelli L, Amoruso A, Mogna L, Graziano T, Cantello R, Pane M, et al. Probiotics May Have Beneficial Effects in Parkinson’s Disease: In vitro Evidence. Front Immunol. 2019; 10: 969.

[20] Ghyselinck J, Verstrepen L, Moens F, Ven Den Abbeele P, Bruggeman A, Said J, et al. Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson’s disease. Int J Pharm X. 2021; 3: 100087.

[21] Hajare S, Kulkarni YA. Parkinson’s disease and the gut-brain connection: unveiling pathways, mechanisms and promising therapies. Brain Res. 2025; 1868: 149975.

[22] Dos Santos JJC, Lima MPP, de Castro Brito GA, de Barros Viana GS. Role of enteric glia and microbiota-gut-brain axis in parkinson disease pathogenesis. Ageing Res Rev. 2023; 84: 101812.

[23] Socała K, Doboszewska U, Szopa A, Serefko A, Włodarczyk M, Zielińska A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol Res. 2021; 172: 105840.

[24] Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol. 2015; 21: 10609-20.

[25] Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Tóth M, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014; 6: 263ra158.

[26] Michel L, Prat A. One more role for the gut: microbiota and blood brain barrier. Ann Transl Med. 2016; 4: 15.

[27] Kalyanaraman B, Cheng G, Hardy M. Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson’s disease and therapeutic implications. Redox Biol. 2024; 71: 103092.

[28] Foster JA, Rinaman L, Cryan JF. Stress & the gut-brain axis: Regulation by the microbiome. Neurobiol Stress. 2017; 7: 124-36.

[29] Lyte M. Microbial endocrinology: Host-microbiota neuroendocrine interactions influencing brain and behavior. Gut Microbes. 2014; 5: 381-9.

[30] Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, et al. Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease. Front Immunol. 2022; 13: 937555.

[31] Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development. J Endocr Soc. 2020; 4: bvz039.

[32] Wang Q, Luo Y, Chaudhuri KR, Reynolds R, Tan E, Pettersson S. The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options. Brain. 2021; 144: 2571-93.

[33] Nie S, Ge Y. The link between the gut microbiome, inflammation, and Parkinson’s disease. Appl Microbiol Biotechnol. 2023; 107: 6737-49.

[34] Rojo ND, Benítez MB, Cava R, Fuentes JM, Cortés SC, Polo RAG. Convergence of Neuroinflammation, Microbiota, and Parkinson’s Disease: Therapeutic Insights and Prospects. Int J Mol Sci. 2024; 25: 11629.

[35] Obrenovich MEM. Leaky Gut, Leaky Brain? Microorganisms. 2018; 6: 107.

[36] Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 2013; 3: 461-91.

[37] Yoo BB, Mazmanian SK. The Enteric Network: Interactions between the Immune and Nervous Systems of the Gut. Immunity. 2017; 46: 910-26.

[38] Brown GC, Camacho M, Williams-Gray CH. The Endotoxin Hypothesis of Parkinson’s Disease. Mov Disord. 2023; 38: 1143-55.

[39] Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022; 22: 657-73.

[40] Luczynski P, Whelan SO, O’Sullivan C, Clarke G, Shanahan F, Dinan TG, et al. Adult microbiota-deficient mice have distinct dendritic morphological changes: differential effects in the amygdala and hippocampus. Eur J Neurosci. 2016; 44: 2654-66.

[41] Heijtz RD, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011; 108: 3047-52.

[42] Kwon D, Zhang K, Paul KC, Folle AD, Rosario ID, Jacobs JP, et al. Diet and the gut microbiome in patients with Parkinson’s disease. NPJ Parkinsons Dis. 2024; 10: 89.

[43] Shen T, Yue Y, He T, Huang C, Qu B, Lv W, et al. The Association Between the Gut Microbiota and Parkinson’s Disease, a Meta-Analysis. Front Aging Neurosci. 2021; 13: 636545.

[44] Toh TS, Chong CW, Lim S, Bowman J, Cirstea M, Lin C, et al. Gut microbiome in Parkinson’s disease: New insights from meta-analysis. Parkinsonism Relat Disord. 2022; 94: 1-9.

[45] Nie S, Wang J, Deng Y, Ye Z, Ge Y. Inflammatory microbes and genes as potential biomarkers of Parkinson’s disease. NPJ Biofilms Microbiomes. 2022; 8: 101.

[46] Mahbub NU, Islam MM, Hong S, Chung H. Dysbiosis of the gut microbiota and its effect on α-synuclein and prion protein misfolding: consequences for neurodegeneration. Front Cell Infect Microbiol. 2024; 14: 1348279.

[47] Schmitt V, Masanetz RK, Weidenfeller M, Ebbinghaus LS, Süß P, Rosshart SP, et al. Gut-to-brain spreading of pathology in synucleinopathies: A focus on molecular signalling mediators. Behav Brain Res. 2023; 452: 114574.

[48] FAO/WHO. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. In: Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria; 2001 Oct 1-4; Córdoba, Argentina. Rome: FAO; 2002.

[49] Kimber IK, Tremblay M. Food for thought: probiotic modulation of microglial activity in Parkinson’s disease. Front Mol Neurosci. 2025; 18: 1690507.

[50] Bi M, Liu C, Wang Y, Liu S. Therapeutic Prospect of New Probiotics in Neurodegenerative Diseases. Microorganisms. 2023; 11: 1527.

[51] Lee YZ, Cheng S, Chang M, Lin Y, Wu C, Tsai Y. Neuroprotective Effects of Lactobacillus plantarum PS128 in a Mouse Model of Parkinson’s Disease: The Role of Gut Microbiota and MicroRNAs. Int J Mol Sci. 2023; 24: 6794.

[52] Liao J, Cheng Y, You S, Kuo W, Huang C, Chiou J, et al. Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson’s disease. Brain Behav Immun. 2020; 90: 26-46.

[53] Lu C, Chang H, Weng Y, Chen C, Kuo Y, Tsai Y. The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson’s Disease: A Pilot Study. Front Nutr. 2021; 8: 650053.

[54] Reiriz M, Beltrán-Velasco AI, Echeverry-Alzate V, Martínez-Miguel E, Gómez-Senent S, Uceda S, et al. Bifidobacterium infantis and Bifidobacterium breve Improve Symptomatology and Neuronal Damage in Neurodegenerative Disease: A Systematic Review. Nutrients. 2025; 17: 391.

[55] Georgescu D, Ancusa OE, Georgescu LA, Ionita I, Reisz D. Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: is there hope? Clin Interv Aging. 2016; 11: 1601-8.

[56] Sun J, Li H, Jin Y, Yu J, Mao S, Su K, et al. Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson’s disease via gut microbiota-GLP-1 pathway. Brain Behav Immun. 2021; 91: 703-15.

[57] Liao B, Ding L, Chen W, Yue M, Wang Y, Hong D, et al. Engineered Clostridium butyricum-pMTL007-GLP-1 Delays Neurodegeneration in Prnp-SNCA*A53T Transgenic Mice Model by Suppressing Astrocyte Senescence. Probiotics Antimicrob Proteins. 2025;[Epub ahead of print].

[58] Wang Y, Chen W, Han Y, Xu X, Yang A, Wei J, et al. Neuroprotective effect of engineered Clostridium butyricum-pMTL007-GLP-1 on Parkinson’s disease mice models via promoting mitophagy. Bioeng Transl Med. 2023; 8: e10505.

[59] Nosrani EA, Tamtaji OR, Alibolandi Z, Sarkar P, Ghazanfari M, Tameh AA, et al. Neuroprotective effects of probiotics bacteria on animal model of Parkinson’s disease induced by 6-hydroxydopamine: A behavioral, biochemical, and histological study. J Immunoassay Immunochem. 2021; 42: 106-20.

[60] Dong X, Yang T, Jin Z. Lactobacillus reuteri-derived γ-amino butyric acid alleviates MPTP-induced Parkinson’s disease through inhibiting ferroptosis via the AKT-GSK3β-GPX4 axis. NPJ Parkinsons Dis. 2025; 11: 149.

[61] Castelli V, d’Angelo M, Quintiliani M, Benedetti E, Cifone MG, Cimini A. The emerging role of probiotics in neurodegenerative diseases: new hope for Parkinson’s disease? Neural Regen Res. 2021; 16: 628-34.

[62] Visñuk DP, de Giori GS, LeBlanc JG, de Moreno de LeBlanc. Neuroprotective effects associated with immune modulation by selected lactic acid bacteria in a Parkinson’s disease model. Nutrition. 2020; 79-80: 110995.

[63] Liu J, Chen Q, Su R. Interplay of human gastrointestinal microbiota metabolites: Short-chain fatty acids and their correlation with Parkinson’s disease. Medicine (Baltimore). 2024; 103: e37960.

[64] Kumar D, Bishnoi M, Kondepudi KK, Sharma SS. Gut Microbiota-Based Interventions for Parkinson’s Disease: Neuroprotective Mechanisms and Current Perspective. Probiotics Antimicrob Proteins. 2025; 17: 2438-60.

[65] Elford JD, Becht N, Garssen J, Kraneveld AD, Perez-Pardo P. Buty and the beast: the complex role of butyrate in Parkinson’s disease. Front Pharmacol. 2024; 15: 1388401.

[66] Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease. Mol Neurodegener. 2021; 16: 6.

[67] Hall DA, Voigt RM, Cantu-Jungles TM, Hamaker B, Engen PA, Shaikh M, et al. An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants. Nat Commun. 2023; 14: 926.

[68] DuPont HL, Suescun J, Jiang Z, Brown EL, Essigmann HT, Alexander AS, et al. Fecal microbiota transplantation in Parkinson’s disease-A randomized repeat-dose, placebo-controlled clinical pilot study. Front Neurol. 2023; 14: 1104759.

[69] Cheng Y, Tan G, Zhu Q, Wang C, Ruan G, Ying S, et al. Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes. 2023; 15: 2284247.

[70] Hamilton AM, Krout IN, White AC, Sampson TR. Microbiome-based therapeutics for Parkinson’s disease. Neurotherapeutics. 2024; 21: e00462.

[71] Magalhães KT, da Silva RNA, Borges AS, Siqueira AEB, Puerari C, Bento JAC. Smart and Functional Probiotic Microorganisms: Emerging Roles in Health-Oriented Fermentation. Fermentation. 2025; 11: 537.

[72] Hong C, Chen J, Huang T. Probiotics treatment for Parkinson disease: a systematic review and meta-analysis of clinical trials. Aging (Albany NY). 2022; 14: 7014-25.

[73] Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015; 386: 896-912.

[74] Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006; 5: 235-45.

[75] Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008; 79: 368-76.

[76] Yin S, Zhu F. Probiotics for constipation in Parkinson’s: A systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2022; 12: 1038928.

[77] Barichella M, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology. 2016; 87: 1274-80.

[78] Tan AH, Lim S, Chong KK, Manap MAAA, Hor JW, Lim JL, et al. Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. Neurology. 2021; 96: e772-82.

[79] Ibrahim A, Ali RAR, Manaf MRA, Ahmad N, Tajurruddin FW, Qin WZ, et al. Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson’s disease: A randomised controlled trial. PLoS One. 2020; 15: e0244680.

[80] Ghalandari N, Assarzadegan F, Habibi SAH, Esmaily H, Malekpour H. Efficacy of Probiotics in Improving Motor Function and Alleviating Constipation in Parkinson’s Disease: A Randomized Controlled Trial. Iran J Pharm Res. 2023; 22: e137840.

[81] Du Y, Li Y, Xu X, Li R, Zhang M, Cui Y, et al. Probiotics for constipation and gut microbiota in Parkinson’s disease. Parkinsonism Relat Disord. 2022; 103: 92-7.

[82] Sun H, Zhao F, Liu Y, Ma T, Jin H, Quan K, et al. Probiotics synergized with conventional regimen in managing Parkinson’s disease. NPJ Parkinsons Dis. 2022; 8: 62.

[83] Chu C, Yu L, Li Y, Guo H, Zhai Q, Chen W, et al. Lactobacillus plantarum CCFM405 against Rotenone-Induced Parkinson’s Disease Mice via Regulating Gut Microbiota and Branched-Chain Amino Acids Biosynthesis. Nutrients. 2023; 15: 1737.

[84] Dong Y, Qi Y, Chen J, Han S, Su W, Ma X, et al. Neuroprotective Effects of Bifidobacterium animalis subsp. lactis NJ241 in a Mouse Model of Parkinson’s Disease: Implications for Gut Microbiota and PGC-1α. Mol Neurobiol. 2024; 61: 7534-48.

[85] Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, et al. The neuropsychiatry of Parkinson’s disease: advances and challenges. Lancet Neurol. 2022; 21: 89-102.

[86] Cong S, Xiang C, Zhang S, Zhang T, Wang H, Cong S. Prevalence and clinical aspects of depression in Parkinson’s disease: A systematic review and metaanalysis of 129 studies. Neurosci Biobehav Rev. 2022; 141: 104749.

[87] Chuquilín-Arista F, Álvarez-Avellón T, Menéndez-González M. Prevalence of Depression and Anxiety in Parkinson Disease and Impact on Quality of Life: A Community-Based Study in Spain. J Geriatr Psychiatry Neurol. 2020; 33: 207-13.

[88] Nisa A, Amalisa RN, Kristantya I, Haryono Y, Nugraha P. Probiotic Supplementation in Parkinson’s Disease: Probiotic supplementation in Parkinson’s diseases. Surabaya Med J. 2024; 2: 73-85.

[89] Park JM, Lee SC, Ham C, Kim YW. Effect of probiotic supplementation on gastrointestinal motility, inflammation, motor, non-motor symptoms and mental health in Parkinson’s disease: a meta-analysis of randomized controlled trials. Gut Pathog. 2023; 15: 9.

[90] Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009; 24: 2175-86.

[91] Kim S, Guevarra RB, Kim Y, Kwon J, Kim H, Cho JH, et al. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J Microbiol Biotechnol. 2019; 29: 1335-40.

[92] Yang X, He X, Xu S, Zhang Y, Mo C, Lai Y, et al. Effect of Lacticaseibacillus paracasei strain Shirota supplementation on clinical responses and gut microbiome in Parkinson’s disease. Food Funct. 2023; 14: 6828-39.

[93] Zeng T, Lin C, Deng Y, Zhu W. Effect of BF 839 + earthworm protein supplement on motor and some non-motor symptoms of Parkinson’s disease: a randomized clinical trial. Front Neurol. 2024; 15: 1371791.

[94] Zandifar A, Badrfam R, Mohammaditabar M, Kargar B, Goodarzi S, Hajialigol A, et al. The Effect of Prebiotics and Probiotics on Levels of Depression, Anxiety, and Cognitive Function: A Meta-Analysis of Randomized Clinical Trials. Brain Behav. 2025; 15: e70401.

[95] Xie C, Prasad AA. Probiotics Treatment Improves Hippocampal Dependent Cognition in a Rodent Model of Parkinson’s Disease. Microorganisms. 2020; 8: 1661.

[96] Videnovic A, Golombek D. Circadian and sleep disorders in Parkinson’s disease. Exp Neurol. 2013; 243: 45-56.

[97] Du Y, Wang L, Cui Y, Xu X, Zhang M, Li Y, et al. Effect of Probiotics Supplementation on REM Sleep Behavior Disorder and Motor Symptoms in Parkinson’s Disease: A Pilot Study. CNS Neurosci Ther. 2025; 31: e70541.

[98] Tan AH, Hor JW, Chong CW, Lim S. Probiotics for Parkinson’s disease: Current evidence and future directions. JGH Open. 2020; 5: 414-9.

[99] Xiang S, Ji J, Li S, Cao X, Xu W, Tan L, et al. Efficacy and Safety of Probiotics for the Treatment of Alzheimer’s Disease, Mild Cognitive Impairment, and Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front Aging Neurosci. 2022; 14: 730036.

[100] Valvaikar S, Vaidya B, Sharma S, Bishnoi M, Kondepudi KK, Sharma SS. Supplementation of probiotic Bifidobacterium breve Bif11 reverses neurobehavioural deficits, inflammatory changes and oxidative stress in Parkinson’s disease model. Neurochem Int. 2024; 174: 105691.

[101] Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024; 9: 37.

[102] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23: 2129-70.

[103] Andreozzi V, Cuoco S, Balestrieri M, Fierro F, Ferrara N, Erro R, et al. Synbiotic supplementation may globally improve non-motor symptoms in patients with stable Parkinson’s disease: results from an open label single-arm study. Sci Rep. 2024; 14: 23095.

[104] Zali A, Hajyani S, Salari M, Tajabadi-Ebrahimi M, Mortazavian AM, Pakpour B. Co-administration of probiotics and vitamin D reduced disease severity and complications in patients with Parkinson’s disease: a randomized controlled clinical trial. Psychopharmacology (Berl). 2024; 241: 1905-14.

[105] Hsieh T, Kuo C, Hsieh K, Shieh M, Peng C, Chen Y, et al. Probiotics Alleviate the Progressive Deterioration of Motor Functions in a Mouse Model of Parkinson’s Disease. Brain Sci. 2020; 10: 206.

[106] Parra I, Martínez I, Vásquez-Celaya L, Gongora-Alfaro JL, Tizabi Y, Mendieta L. Neuroprotective and Immunomodulatory Effects of Probiotics in a Rat Model of Parkinson’s Disease. Neurotox Res. 2023; 41: 187-200.

[107] Leta V, Mandal G, Zinzalias P, Staunton J, Batzu L, Trivedi D, et al. Effects of a four-strain probiotic on inflammatory markers in Parkinson’s disease: a multicentre randomised controlled trial (the SymPD study) (N5.001). Neurology. 2024; 102: 7_supplement_1.

[108] Atak ES, Yıldız D, Kocatürk RR, Temizyürek A, Özcan ÖÖ, Ergüzel TT, et al. Therapeutic Targets of Probiotics in Parkinson Disease: A Systematic Review of Randomized Controlled Trials. Basic Clin Neurosci. 2024; 15: 165-74.

[109] Brusnic O, Adrian B, Sorin-Radu F, Grama B, Sofonea F, Roman-Filip C, et al. Importance of Fecal Microbiota Transplantation and Molecular Regulation as Therapeutic Strategies in Inflammatory Bowel Diseases. Nutrients. 2024; 16: 4411.

[110] Eslami M, Adampour Z, Dowlat BF, Yaghmayee S, Tabaei FM, Oksenych V, et al. A Novel Frontier in Gut-Brain Axis Research: The Transplantation of Fecal Microbiota in Neurodegenerative Disorders. Biomedicines. 2025; 13: 915.

[111] Bruggeman A, Vandendriessche C, Hamerlinck H, Looze DD, Tate DJ, Vuylsteke M, et al. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson’s disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine. 2024; 71: 102563.

[112] Scheperjans F, Levo R, Bosch B, Lääperi M, Pereira PAB, Smolander O, et al. Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2024; 81: 925-38.

[113] Chen K, Sun L, Liu Y, Chen R. Safety and efficacy of fecal microbiota transplantation in the treatment of Parkinson’s disease: a systematic review of clinical trials. Front Neurosci. 2025; 19: 1639911.

[114] Nagpal R, Wang S, Woods LCS, Seshie O, Chung ST, Shively CA, et al. Comparative Microbiome Signatures and Short-Chain Fatty Acids in Mouse, Rat, Non-human Primate, and Human Feces. Front Microbiol. 2018; 9: 2897.

[115] Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004; 172: 2731-8.

[116] MacLean EL. Unraveling the evolution of uniquely human cognition. Proc Natl Acad Sci U S A. 2016; 113: 6348-54.

[117] Menozzi E, Schapira AHV. The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications. CNS Drugs. 2024; 38: 315-31.

[118] Zheng Y, Zhang Z, Tang P, Wu Y, Zhang A, Li D, et al. Probiotics fortify intestinal barrier function: a systematic review and meta-analysis of randomized trials. Front Immunol. 2023; 14: 1143548.

[119] Chuang Y, Fan K, Su Y, Wu M, Chiu Y, Liu Y, et al. Precision probiotics supplement strategy in aging population based on gut microbiome composition. Brief Bioinform. 2024; 25: bbae351.

[120] de Almeida Brasiel PG, Luquetti SCPD. Effects of Probiotics Supplementation on Short-Chain Fatty Acids: A Systematic Review of Randomized Controlled Trials. Nutr Rev. 2025; 83: 1892-907.

[121] Sreenikitha K, Das S, Andrighetti T, Sudhakar P. Comparative study of the gut microbiomes between Western and Indigenous cultures - Implications for health and disease. The Microbe. 2025; 7: 100310.

[122] Low DY, Hejndorf S, Tharmabalan RT, Poppema S, Pettersson S. Regional Diets Targeting Gut Microbial Dynamics to Support Prolonged Healthspan. Front Microbiol. 2021; 12: 659465.

[123] Gu X, Tang J, Chen C. Efficacy of gut microbiota-targeted therapies in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2025; 15: 1627406.